BioAge Labs downgraded to Underweight from Overweight at Morgan Stanley

Morgan Stanley downgraded BioAge Labs (BIOA) to Underweight from Overweight with a price target of $5, down from $40. The company discontinued its STRIDES trial following cases of liver transaminitis, which removes the key clinical catalyst for next year, the analyst tells investors in a research note. The firm downgraded shares on a relative basis as it sees better opportunities elsewhere for 2025.